Search Within

Robert Motzer

Formats
  1. Journal Article (609)
  2. Meeting Abstract (574)
  3. Book Section (20)
  4. Review (13)
  5. Conference Paper (6)
  6. Correspondence (6)
  7. Guidelines (5)
  8. Research Letter (5)
  9. Editorial (3)
  10. Book Whole (2)
Groups
  1. Department of Medicine (1243)
  2. Genitourinary Oncology Service (1243)
  3. Solid Tumor Oncology Division (1243)
  4. Surgery (288)
  5. Urology (279)
  6. Survivorship Research (252)

More Groups

People
  1. George Bosl (182)
  2. Martin Voss (176)
  3. Darren Feldman (157)
  4. Dean Bajorin (128)
  5. Paul Russo (119)
  6. Joel Sheinfeld (110)

More People

Years
  1. 2025 (26)
  2. 2024 (49)
  3. 2023 (47)
  4. 2022 (64)
  5. 2021 (65)
  6. 2020 (65)

More Years

Publications
  1. Journal of Clinical Oncology (444)
  2. Annals of Oncology (81)
  3. BJU International (40)
  4. Cancer (35)
  5. European Journal of Cancer (34)
  6. Clinical Cancer Research (33)

More Publications

Publishers
  1. American Society of Clinical Oncology (447)
  2. Elsevier Science, Inc. (111)
  3. Oxford University Press (111)
  4. Elsevier Inc. (89)
  5. Wiley Blackwell (86)
  6. American Association for Cancer Research (58)

More Publishers

Results (1243)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Management of kidney cancer relapse to adjuvant pembrolizumab: Early insights and questions for a newly emerging space
    Editorial

    Voss, M. H.; Motzer, R. J.
    European Urology (2024)

    Fulltext@MSK | Save
  • Nivolumab plus relatlimab and nivolumab plus ipilimumab for patients with advanced renal cell carcinoma: Results from the open-label, randomised, phase II FRACTION-RCC trial
    Journal Article

    Choueiri, T. K.; Kuzel, T. M.; Tykodi, S. S.; Verzoni, E.; Kluger, H.; Nair, S.; Perets, R.; George, S.; Gurney, H.; Pachynski, R. K.; more...
    ESMO Open (2024)

    Fulltext@MSK | Save
  • Lenvatinib plus Pembrolizumab following immune checkpoint inhibitor treatment in patients with metastatic clear cell renal cell carcinoma: Results from study 111/KEYNOTE-146
    Research Letter

    Lee, C. H.; Yogesh Shah, A.; Rao, A.; Taylor, M. H.; Di Simone, C.; Hsieh, J. J.; Pinto, A.; Gironés Sarrió, R.; Lee Cohn, A.; Asim Bilen, M.; more...
    European Urology (2024)

    Fulltext@MSK | Save
  • Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: Results of the phase 3 TiNivo-2 study
    Journal Article

    Choueiri, T. K.; Albiges, L.; Barthélémy, P.; Iacovelli, R.; Emambux, S.; Molina-Cerrillo, J.; Garmezy, B.; Barata, P.; Basu, A.; Bourlon, M. T.; more...
    Lancet (2024)

    Fulltext@MSK | Save
  • Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: Extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial
    Journal Article

    Tannir, N. M.; Albigès, L.; McDermott, D. F.; Burotto, M.; Choueiri, T. K.; Hammers, H. J.; Barthélémy, P.; Plimack, E. R.; Porta, C.; George, S.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Adjuvant nivolumab monotherapy vs placebo for localized renal cell carcinoma at high risk of relapse after nephrectomy: Results from Part B of the randomized, phase 3 CheckMate 914 trial
    Meeting Abstract

    Motzer, R. J.; Bex, A.; Russo, P.; Tomita, Y.; Cutuli, H.; Rojas, C.; Gross-Goupil, M.; Schinzari, G.; Melichar, B.; Barthelemy, P.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Evolving metastatic renal cell carcinoma (mRCC) treatment landscape in the post vascular endothelial growth factor (VEGF) and immune checkpoint inhibitor (IO) setting
    Meeting Abstract

    Shah, N. J.; Bhattacharya, R.; Ning, N.; Shinde, R.; Schmier, J.; Tan, M. L. D.; Lemasters, T.; Sundaram, M.; Perini, R. F.; Motzer, R. J.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Subgroup analyses of efficacy outcomes by baseline tumor size in the phase 3, open-label CLEAR trial
    Meeting Abstract

    Grünwald, V.; Motzer, R. J.; Haanen, Jbag; Schmidinger, M.; Staehler, M. D.; Goh, J. C.; Voog, E.; Climent, M. A.; George, S.; Burgents, J. E.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Hypoxia-inducible factor-2 alpha (HIF-2α) target activation and clinical outcomes in 942 patients with clear cell renal cell carcinoma
    Meeting Abstract

    Doshi, S. D.; Kuo, F.; Knezevic, A.; Kotecha, R. R.; Motzer, R. J.; Hakimi, A. A.; Voss, M. H.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Nivolumab plus ipilimumab (NIVO + IPI) vs sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC): Long-term follow-up data from the phase 3 CheckMate 214 trial
    Meeting Abstract

    Escudier, B.; McDermott, D. F.; Burotto, M.; Choueiri, T. K.; Hammers, H. J.; Plimack, E. R.; Porta, C.; George, S.; Powles, T.; Donskov, F.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save